## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.42 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($170.27)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Copeland Capital Management LLC Sells 7,889 Shares of Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251230T101413 | Neutral | Relevance: 100%
- Copeland Capital Management LLC reduced its stake in Quest Diagnostics Incorporated by 4.5% during the third quarter, selling 7,889 shares and retaining 168,375 shares valued at approximately $32.09 million. This sale comes amidst significant insider selling, with SVP Mark Delaney and CEO J. E. Davis also disposing of shares worth millions. Despite the insider and institutional selling, Quest Diagnostics beat Q3 earnings estimates, issued strong FY2025 guidance, and analysts maintain a "Moderate Buy" rating with an average target price of $197.27.

**2. Harbor Capital Advisors Inc. Has $596,000 Stake in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251228T111115 | Neutral | Relevance: 100%
- Harbor Capital Advisors Inc. reduced its stake in Quest Diagnostics (NYSE:DGX) by 71% in the third quarter, now holding 3,128 shares valued at $596,000. Despite this, other institutional investors have increased their positions, with collectively 88.06% of the stock owned by institutional investors and hedge funds. Quest Diagnostics surpassed Q3 earnings expectations, reporting EPS of $2.60 against an anticipated $2.51, and revealed intentions to pay a quarterly dividend of $0.80 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($1.18M) |
| Sells | 5 ($3.52M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $3.5M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.42 suggests fair value with growth premium. Forward P/E 16.9x stretched relative to 6% growth. Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.6B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.42 |
| Forward P/E | 16.9 |
| Current P/E | 17.9 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.7% to -2.2% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 6.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.4%) - potential reversal signal. Underperforming sector by 3.4pp, stock-specific weakness. Below SMA200 (0.99x), long-term trend not supportive. OFD pattern: -SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.24% (CS: 19) | Weak |
| RSI_14 | 37.0 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.964x | Below |
| vs SMA200 | 0.990x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $175.49
- **Stop Loss:** $170.27 (3.0% risk)
- **Target:** $185.93 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 252
- **Position Value:** $44,223.48
- **Portfolio %:** 44.22%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*